What is the address of Dr. H. DE SAMBLANX, Inwendige Geneeskunde?

The registered office of Dr. H. DE SAMBLANX, Inwendige Geneeskunde is located at Rode-Leeuwstraat(MRH) 23, 2200 Herentals.

Is Dr. H. DE SAMBLANX, Inwendige Geneeskunde still active?

Yes. According to the CBE (30 September 2026) Dr. H. DE SAMBLANX, Inwendige Geneeskunde is active, legal situation “Normale toestand”, started on 15 June 2005.

Is Dr. H. DE SAMBLANX, Inwendige Geneeskunde registered on Peppol?

Yes, Dr. H. DE SAMBLANX, Inwendige Geneeskunde is registered on the Peppol network with ID 0208:0874469450.

What is the enterprise number of Dr. H. DE SAMBLANX, Inwendige Geneeskunde?

The enterprise number of Dr. H. DE SAMBLANX, Inwendige Geneeskunde is BE0874469450.

When was Dr. H. DE SAMBLANX, Inwendige Geneeskunde founded?

Dr. H. DE SAMBLANX, Inwendige Geneeskunde was founded on 15 June 2005.

Who are the directors of Dr. H. DE SAMBLANX, Inwendige Geneeskunde?

According to the 2025 annual accounts, the directors of Dr. H. DE SAMBLANX, Inwendige Geneeskunde are: Hadewijch De Samblanx.

Is Dr. H. DE SAMBLANX, Inwendige Geneeskunde a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 June 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. H. DE SAMBLANX, Inwendige Geneeskunde make in 2025?

Dr. H. DE SAMBLANX, Inwendige Geneeskunde posted a profit after taxes of € 193,507 in financial year 2025.

What is the revenue of Dr. H. DE SAMBLANX, Inwendige Geneeskunde?

As a small company, Dr. H. DE SAMBLANX, Inwendige Geneeskunde is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 279,218.

Dr. H. DE SAMBLANX, Inwendige Geneeskunde (Private Limited)

Dossier Dr. H. DE SAMBLANX, Inwendige Geneeskunde, printed on 30 September 2026 from databakkes.be/en/0874469450/dr-h-de-samblanx-inwendige-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. H. DE SAMBLANX, Inwendige Geneeskunde from Herentals, company number BE0874469450, closed financial year 2025 with a result of € 193,507 after tax. For that financial year Dr. H. DE SAMBLANX, Inwendige Geneeskunde recorded a gross margin of € 279,218 and equity of € 845,264. Compared with financial year 2024, the result moved from € 177,114 to € 193,507. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 845,264

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 193,507

▲ 9% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 560,147

▲ 102% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 71,812 paid out

37 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 21,008

▼ 28% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 225

▼ 37% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 58,657

▲ 75% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	€ 338,768 Revenue 2024: € 338,768 First fiscal year in the series	-
Gross margin	€ 178,058 Gross margin 2022: € 178,058 First fiscal year in the series	€ 170,087 Gross margin 2023: € 170,087 ▼ 4% vs 2022 (€ 178,058) Unfavourable step	€ 258,610 Gross margin 2024: € 258,610 ▲ 52% vs 2023 (€ 170,087) Favourable step	€ 279,218 Gross margin 2025: € 279,218 ▲ 8% vs 2024 (€ 258,610) Favourable step	▲ 8%
Profit after taxes	€ 124,392 Profit after taxes 2022: € 124,392 First fiscal year in the series	€ 113,864 Profit after taxes 2023: € 113,864 ▼ 8% vs 2022 (€ 124,392) Unfavourable step	€ 177,114 Profit after taxes 2024: € 177,114 ▲ 56% vs 2023 (€ 113,864) Favourable step	€ 193,507 Profit after taxes 2025: € 193,507 ▲ 9% vs 2024 (€ 177,114) Favourable step	▲ 9%
Equity	€ 602,487 Equity 2022: € 602,487 First fiscal year in the series	€ 637,990 Equity 2023: € 637,990 ▲ 6% vs 2022 (€ 602,487) Favourable step	€ 723,569 Equity 2024: € 723,569 ▲ 13% vs 2023 (€ 637,990) Favourable step	€ 845,264 Equity 2025: € 845,264 ▲ 17% vs 2024 (€ 723,569) Favourable step	▲ 17%
Total debts	€ 1,166 Total debts 2022: € 1,166 First fiscal year in the series	€ 11,460 Total debts 2023: € 11,460 ▲ € 10,295 vs 2022 (€ 1,166) Unfavourable step	€ 33,862 Total debts 2024: € 33,862 ▲ 195% vs 2023 (€ 11,460) Unfavourable step	€ 58,882 Total debts 2025: € 58,882 ▲ 74% vs 2024 (€ 33,862) Unfavourable step	▲ 74%
Cash	€ 299,841 Cash 2022: € 299,841 First fiscal year in the series	€ 164,652 Cash 2023: € 164,652 ▼ 45% vs 2022 (€ 299,841) Unfavourable step	€ 277,523 Cash 2024: € 277,523 ▲ 69% vs 2023 (€ 164,652) Favourable step	€ 560,147 Cash 2025: € 560,147 ▲ 102% vs 2024 (€ 277,523) Favourable step	▲ 102%
Retained profit	€ 589,987 Retained profit 2022: € 589,987 First fiscal year in the series	€ 625,490 Retained profit 2023: € 625,490 ▲ 6% vs 2022 (€ 589,987) Favourable step	€ 711,069 Retained profit 2024: € 711,069 ▲ 14% vs 2023 (€ 625,490) Favourable step	€ 832,764 Retained profit 2025: € 832,764 ▲ 17% vs 2024 (€ 711,069) Favourable step	▲ 17%
Dividend	€ 78,015 Dividend 2022: € 78,015 First fiscal year in the series	€ 78,361 Dividend 2023: € 78,361 Unchanged (€ 78,015) Unchanged	€ 91,535 Dividend 2024: € 91,535 ▲ 17% vs 2023 (€ 78,361) Unchanged	€ 71,812 Dividend 2025: € 71,812 ▼ 22% vs 2024 (€ 91,535) Unchanged	▼ 22%
Balance sheet total	€ 603,653 Balance sheet total 2022: € 603,653 First fiscal year in the series	€ 649,450 Balance sheet total 2023: € 649,450 ▲ 8% vs 2022 (€ 603,653) Unchanged	€ 757,431 Balance sheet total 2024: € 757,431 ▲ 17% vs 2023 (€ 649,450) Unchanged	€ 904,146 Balance sheet total 2025: € 904,146 ▲ 19% vs 2024 (€ 757,431) Unchanged	▲ 19%

Key figures of Dr. H. DE SAMBLANX, Inwendige Geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. H. DE SAMBLANX, Inwendige Geneeskunde?

What happened at Dr. H. DE SAMBLANX, Inwendige Geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 193,507 (▲ 9% vs 2024). filed late Source: NBB ↗
2005 Hadewijch De Samblanx became a director. NBB
Jun 15, 2005 Start of the company according to the CBE. KBO
May 31, 2005 New establishment in Herentals. KBO

In short

From € 124,392 profit in 2022 to € 193,507 profit in 2025.

Paid € 262,207 in corporate taxes since 2022.

Best year ever: 2025, with € 193,507 profit.

Paid out € 319,723 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. H. DE SAMBLANX, Inwendige Geneeskunde? We notify you, reason included.

Follow Dr. H. DE SAMBLANX, Inwendige Geneeskunde

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Hadewijch De Samblanx

Dr. H. DE SAMBLANX, Inwendige Geneeskunde

Behind Dr. H. DE SAMBLANX, Inwendige Geneeskunde is Hadewijch De Samblanx.

See the full network in the app

Directors

According to the 2025 annual accounts

Hadewijch De Samblanx

Director

since 2005

Establishments

Establishment units

Physical locations of this company

Registered office

Rode-Leeuwstraat(MRH) 23

2200 Herentals

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0874.469.450
VAT number: BE 0874.469.450
Registered office: Rode-Leeuwstraat(MRH) 23, 2200 Herentals
Names & denominations: Dr. H. DE SAMBLANX, Inwendige Geneeskunde
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 15 June 2005
Peppol: Active · Active since 5 Aug 2025

View on CBE Public ↗ Annual accounts (NBB) ↗